Dolutegravir Adverse Drug Events: Thai HIV Patients
- Okay, here's a breakdown of the key points from the provided text, focusing on renal (kidney) health and Dolutegravir (DTG) use in people living with HIV:
- * Renal ADEs (Adverse Drug Events) are a concern: The study investigated factors associated with kidney-related side effects in people starting Dolutegravir (DTG)-based antiretroviral therapy (ART).
- * DTG (Dolutegravir): An antiretroviral drug used to treat HIV.
Okay, here’s a breakdown of the key points from the provided text, focusing on renal (kidney) health and Dolutegravir (DTG) use in people living with HIV:
Main Findings & Takeaways:
* Renal ADEs (Adverse Drug Events) are a concern: The study investigated factors associated with kidney-related side effects in people starting Dolutegravir (DTG)-based antiretroviral therapy (ART).
* Baseline Kidney Function Matters: People with pre-existing kidney impairment (eGFR < 90 mL/min/1.73 m) were at higher risk of developing renal ADEs.
* TDF vs. DTG: While DTG can cause a small, reversible increase in creatinine (a kidney function marker), the study suggests that Tenofovir Disoproxil Fumarate (TDF) is more likely to be the cause of significant kidney function decline in this cohort. This means the observed kidney problems are likely more related to TDF than DTG itself.
* Alternative Regimens: For patients with kidney issues or risk factors, switching to regimens without TDF (like TAF/FTC/DTG, or DTG/3TC/RPV) is recommended, especially if they don’t have Hepatitis B co-infection.
* Longer ART Duration Before DTG is Protective: Interestingly, people who had been on ART for a longer time before starting DTG had a lower risk of renal ADEs. This could be due to:
* Survivor Bias: Those who have stayed on ART for a long time may be a healthier, more resilient group.
* Treatment Tolerance: Long-term ART exposure might lead to some level of kidney adaptation.
* Further Research Needed: The protective effect of longer ART duration needs more examination to understand the underlying reasons.
Key Concepts/Terms:
* DTG (Dolutegravir): An antiretroviral drug used to treat HIV.
* TDF (Tenofovir Disoproxil Fumarate): An older antiretroviral drug that can sometimes cause kidney problems.
* TAF (Tenofovir Alafenamide): A newer version of Tenofovir that is generally considered less toxic to the kidneys than TDF.
* eGFR (estimated Glomerular Filtration Rate): A measure of kidney function.
* OCT2 and MATE1: Renal tubular transporters inhibited by DTG, leading to a slight creatinine increase.
* ADEs (Adverse Drug Events): Undesirable medical occurrences related to drug use.
* ART (Antiretroviral Therapy): Medications used to treat HIV.
* HBV (Hepatitis B Virus): A viral infection that can affect the liver.
* FTC (Emtricitabine): An antiretroviral drug.
* 3TC (Lamivudine): An antiretroviral drug.
* RPV (Rilpivirine): An antiretroviral drug.
In essence,the study highlights the importance of considering kidney health when starting DTG-based ART,notably in patients with pre-existing kidney problems. It suggests that TDF is a bigger contributor to kidney issues than DTG itself, and that alternative regimens should be considered when appropriate.